Does Haemonetics (HAE) Have Enduring Growth Potential?
Aristotle Capital Boston, LLC, an investment advisor, released its first-quarter 2026 investor letter for “Small Cap Equity Fund”. A copy of the letter is available to download here. U.S.
Haemonetics Corp (HAE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 3,356,543 | $185,683,959 | +7% | 0.09% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,383,004 | $77,946,105 | +1% | 0.04% |
| 3. | North Peak Capital Michael Kahan And Jeremy Kahan | 998,953 | $56,300,991 | -10% | 9.36% |
| 4. | Invenomic Capital Management Ali Motamed | 664,729 | $37,464,126 | 1.72% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 320,010 | $18,035,763 | -27% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.56 | 1,400 | $98,784.00 | 24,757 | 2025-11-10 | Filing | |
| $80.93 | 4,000 | $323,720.00 | 12,048 | 2020-08-11 | Filing | |
| $35.00 | 60,000 | $2,099,754.00 | 105,867 | 2016-08-04 | Filing | |
| $32.73 | 412 | $13,482.70 | 31,522 | 2013-04-30 | Filing | |
| $32.73 | 615 | $20,125.88 | 17,279 | 2013-04-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.15 | 4,312 | $393,038.80 | 18,196 | 2024-07-26 | Filing | |
| $90.00 | 79 | $7,110.00 | 21,331 | 2024-07-12 | Filing | |
| $90.00 | 2,136 | $192,240.00 | 21,410 | 2024-07-11 | Filing | |
| $88.57 | 4,094 | $362,605.58 | 31,257 | 2024-05-29 | Filing | |
| $87.86 | 8,896 | $781,602.56 | 35,351 | 2024-05-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,619,979 | $316,742,027 | 0.01% | |
| 2. | 3,560,918 | $200,613,400 | 0.15% | |
| 3. | 189,401,000 | $180,539,633 | 1.01% | |
| 4. | 2,559,316 | $144,243,050 | 0% | |
| 5. | 2,090,389 | $117,814,324 | 0% |
News See All
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript
Operator: Hello, and welcome to the Q4 2026 Haemonetics Corporation's earnings conference call. [Operator Instructions] Please be advised that today's conference is being recorded.
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q1 2026 investor letter. A copy of the letter can be downloaded here.
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
TheFly reported on April 13 that Mizuho analyst Anthony Petrone reduced the price target for HAE to $70 from $80 while maintaining an Outperform rating.
10 Best Healthcare Stocks to Buy and Hold for 3 Years
The first quarter of this year has seen a great deal of volatility in the equity markets. The S&P 500 fell into correction territory before rising again after first soaring to all-time highs.
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating.
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth
Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Haemonetics Corporation (NYSE:HAE) Q3 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2026 Haemonetics Corporation Earnings Conference Call. At this time, participants are in a listen-only mode.
Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition
On January 12, Michael Petusky from Barrington maintained his Outperform rating on Haemonetics Corporation (NYSE:HAE).
Hedge Fund Resource Center